{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:31:47Z","timestamp":1790947907064,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Rouen University Hospital","award":["2012\/056\/HP"],"award-info":[{"award-number":["2012\/056\/HP"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.thromres.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T19:31:12Z","timestamp":1492025472000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study"],"prefix":"10.1016","volume":"155","author":[{"given":"S\u00e9bastien","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Le Cam-Duchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Benichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Donnadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Barbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelle","family":"Le Besnerais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-1845","authenticated-orcid":false,"given":"Antoine","family":"Cuvelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2017.04.011_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/003693308102600205","article-title":"Prevention of deep vein thrombosis in medical patients by low-dose heparin","volume":"26","author":"Belch","year":"1981","journal-title":"Scott. Med. J."},{"key":"10.1016\/j.thromres.2017.04.011_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group","volume":"341","author":"Samama","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2017.04.011_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2017.04.011_bb0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended Thromboprophylaxis with Betrixaban in acutely ill medical patients","author":"Cohen","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0045","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/jth.12106","article-title":"Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency","volume":"11","author":"Galanaud","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0055","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1586\/erc.10.160","article-title":"Prevention of venous thromboembolism in obesity","volume":"8","author":"Freeman","year":"2010","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.thromres.2017.04.011_bb0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archinte.165.3.341","article-title":"Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial","volume":"165","author":"Kucher","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of Enoxaparin in obese volunteers","volume":"72","author":"Sanderink","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2017.04.011_bb0070","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0075","author":"Lovenox Summary of Product Characteristics"},{"key":"10.1016\/j.thromres.2017.04.011_bb0080","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0300-2896(08)75774-0","article-title":"Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass","volume":"44","author":"Jim\u00e9nez","year":"2008","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.thromres.2017.04.011_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.ijo.0800435","article-title":"Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution","volume":"21","author":"De Pergola","year":"1997","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.thromres.2017.04.011_bb0090","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2010.03766.x","article-title":"Thrombin generation in morbid obesity: significant reduction after weight loss","volume":"8","author":"Ay","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0095","article-title":"Relation between weight, obesity, and frequency of deep vein Thrombosis after Enoxaparin on orthopedic surgery","author":"Samama","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement","volume":"62","author":"Levine","year":"1989","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11695-007-9381-y","article-title":"Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin","volume":"18","author":"Rowan","year":"2008","journal-title":"Obes. Surg."},{"key":"10.1016\/j.thromres.2017.04.011_bb0110","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00464-008-9997-6","article-title":"Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery","volume":"22","author":"Simone","year":"2008","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.thromres.2017.04.011_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.soard.2007.11.010","article-title":"Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity","volume":"4","author":"Borkgren-Okonek","year":"2008","journal-title":"Surg. Obes. Relat. Dis."},{"key":"10.1016\/j.thromres.2017.04.011_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11695-008-9738-x","article-title":"Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery","volume":"20","author":"Simoneau","year":"2010","journal-title":"Obes. Surg."},{"key":"10.1016\/j.thromres.2017.04.011_bb0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.thromres.2009.02.003","article-title":"Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients","volume":"125","author":"Rondina","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.04.011_bb0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.23228","article-title":"Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity","volume":"87","author":"Freeman","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2017.04.011_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0049-3848(02)00028-2","article-title":"Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin","volume":"105","author":"Mayr","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.04.011_bb0140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1310\/hpj4908-740","article-title":"Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity","volume":"49","author":"Shelkrot","year":"2014","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.thromres.2017.04.011_bb0145","series-title":"Annales Francaises D'anesthesie Et De Reanimation","first-page":"947","article-title":"French Society of Anaesthesia and Intensive Care. Guidelines on perioperative venous thromboembolism prophylaxis. Update 2011. Short text","volume":"30","author":"Samama","year":"2011"},{"key":"10.1016\/j.thromres.2017.04.011_bb0150","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in Nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2017.04.011_bb0155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/oby.20461","volume":"21","author":"Mechanick","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.thromres.2017.04.011_bb0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1008740","article-title":"Clinical practice. Deep-vein thrombosis of the upper extremities","volume":"364","author":"Kucher","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0165","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archinte.164.9.963","article-title":"Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study","volume":"164","author":"Alikhan","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0170","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.04.011_bb0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0049-3848(99)00110-3","article-title":"Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy","volume":"96","author":"Pettil\u00e4","year":"1999","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.04.011_bb0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5858\/2004-128-519-COPCPW","article-title":"Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study","volume":"128","author":"Desjardins","year":"2004","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.thromres.2017.04.011_bb0185","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.thromres.2017.04.011_bb0190","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/AOG.0b013e31819b3b38","article-title":"Anti-factor xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis","volume":"113","author":"Pabinger","year":"2009","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.thromres.2017.04.011_bb0195","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.thromres.2009.04.021","article-title":"Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study)","volume":"124","author":"Imberti","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.04.011_bb0200","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-009-0418-z","article-title":"Using low molecular weight heparin in special patient populations","volume":"29","author":"Lim","year":"2010","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817302797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817302797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T12:55:57Z","timestamp":1658926557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384817302797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":40,"alternative-id":["S0049384817302797"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2017.04.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}